Three classes of propofol binding sites on GABA A receptors.

Propofol is a widely used anesthetic and sedative that acts as a positive allosteric modulator (PAM) of gamma-aminobutyric acid type A (GABA _A ) receptors. Several potential propofol binding sites that may mediate this effect have been identified using propofol-analogue photoaffinity labeling. o-PD labels β-H267, a pore-lining residue, whereas AziPm labels residues β-M286, β-M227 and α-I239 in the two membrane-facing interfaces (β(+)/α(-) and α(+)/β(-)) between α and β subunits. This study used photoaffinity labeling of α ₁ β ₃ GABA _A receptors to reconcile the apparently conflicting results obtained with AziPm and o-PD labeling, focusing on whether β ₃ -H267 identifies specific propofol binding site(s). The results show that propofol, but not AziPm protects β ₃ -H267 from labeling by o-PD, whereas both propofol and o-PD protect against AziPm labeling of β ₃ -M286, β ₃ -M227 and α ₁ I239. These data indicate that there are three distinct classes of propofol binding sites, with AziPm binding to two of the classes and o-PD to all three. Analysis of binding stoichiometry using native mass spectrometry in β ₃ homomeric receptors, demonstrated a minimum of five AziPm labeled residues and three o-PD labeled residues per pentamer, suggesting that there are two distinct propofol binding sites per β-subunit. The native MS data, coupled with photolabeling performed in the presence of zinc, indicate that the binding site(s) identified by o-PD are adjacent to, but not within the channel pore, since the pore at the 17' H267 residue can accommodate only one propofol molecule. These data validate the existence of three classes of specific propofol binding sites on α ₁ β ₃ GABA _A receptors.
Competing Interests: Conflict of Interest The authors declare that they have no conflicts of interest with the contents of this article
(Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)